ReviewNeuroscience bulletin2025
The Role of Neuroinflammation and Network Anomalies in Drug-Resistant Epilepsy.
Review in Neuroscience bulletin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The levels of miR-155 in epilepsy patients: a meta-analysis.Frontiers in neurology · 2025Pooled it
- Antiepileptic and antiepileptogenic effects ofIBRO neuroscience reports · 2026Article
- Etiology-specific trajectories of longitudinal functional connectivity and network topology in posttraumatic and mesial temporal lobe epileptogenesis.Experimental neurology · 2026Article
- Review
- Multilayer Validation Reveals a Glia-Associated Secretome Signature in Temporal Lobe Epilepsy.Journal of molecular neuroscience : MN · 2026Article
- Nonlinear Association Between the C-Reactive Protein-To-Albumin Ratio and Post-Stroke Epilepsy Risk.CNS neuroscience & therapeutics · 2026Article
- Anti-Inflammatory Effects of Progesterone on Human Microglia via TLR4/NLRP3 Pathway Modulation: Relevance to Drug-Resistant Epilepsy.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Chronic sleep deprivation promotes drug-resistant epilepsy via the BMAL1-mTOR-P-gp axis.Epilepsia open · 2026Article
- Immunomodulatory Effects of Anti-Epileptic Drug Lacosamide on Mammalian Macrophages.Cell biochemistry and biophysics · 2026Article
- From insult to hyperexcitability: pharmacological targeting of MyD88 and JAK/STAT3 pathways in epilepsy.Inflammopharmacology · 2026Review
- Microglial-Derived Cholesterol 25-Hydroxylase Promotes Epileptic Seizure and Neuroinflammation Mediated by NLRP3 Inflammasome and Lipid Metabolism.Neuroscience bulletin · 2026Article
- Glymphatic system dysfunction in epilepsy: a review of mechanisms and clinical evidence.Encephalitis (Seoul, Korea) · 2026Article
- Integrated metabolomic and transcriptomic profiling reveals lipid dysregulation and potential biomarkers in interstitial lung disease.Frontiers in immunology · 2026Article
- Editorial: Cannabidiol: perspectives on drug-resistant epilepsy management.Frontiers in pharmacology · 2026Article
- The Changing Paradigm of Neuroinflammation in Epilepsy: A Bibliometric Analysis from Microglial Activation to Gut-Brain Axis.Journal of inflammation research · 2026Review
- Gastrodin alleviates neuronal damage in epileptic cell models by targeting P2RY12 to inhibit microglial hyperactivation.PloS one · 2026Article
- Elevated Apolipoprotein E Expression in Hippocampal Microglia Drives Temporal Lobe Epilepsy Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- APOE-Glia Crosstalk in Epilepsy: Mechanisms, Controversies, and Therapeutic Perspectives.Journal of inflammation research · 2026Review
- Innate immune signalling, neuroinflammation and network plasticity in temporal lobe epilepsy.Frontiers in pharmacology · 2026Review
- Elucidating the putative role of cannabigerol: a hypothesis-generating review of neuroinflammatory and neuroprotective mechanisms with implications for drug-resistant epilepsy.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy affects over 50 million people worldwide. Drug-resistant epilepsy (DRE) accounts for up to a third of these cases, and neuro-inflammation is thought to play a role in such cases. Despite being a long-debated issue in the field of DRE, the mechanisms underlying neuroinflammation have yet to be fully elucidated. The pro-inflammatory microenvironment within the brain tissue of people with DRE has been probed using single-cell multimodal transcriptomics. Evidence suggests that inflammatory cells and pro-inflammatory cytokines in the nervous system can lead to extensive biochemical changes, such as connexin hemichannel excitability and disruption of neurotransmitter homeostasis. The presence of inflammation may give rise to neuronal network abnormalities that suppress endogenous antiepileptic systems. We focus on the role of neuroinflammation and brain network anomalies in DRE from multiple perspectives to identify critical points for clinical application. We hope to provide an insightful overview to advance the quest for better DRE treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.